危重患者增强CT后肾小球滤过率的测定:支持一种新方法
这项前瞻性观察性队列研究在瑞典东南部多个ICU纳入26例危重成人患者,在增强CT时给予高剂量碘海醇(27-140 mL),于消除相采血用高效液相色谱法测定血浆碘海醇浓度并计算mGFRiohexol,随后数日给予标准剂量(5 mL)碘海醇比较低剂量清除率结果,并每日4次测定6小时尿肌酐清除率取平均值。结果显示增强CT后mGFRiohexol为77.4 ± 38.1 mL/min(n = 26),uClcr为97.3 ± 58.2 mL/min(n = 25);高剂量与低剂量碘海醇测定的mGFRiohexol在mGFR正常或偏高的患者中强正相关(R2 = 0.88;p < 0.001),mGFRiohexol与uClcr亦强正相关(R2 = 0.87;p < 0.001);eGFRcr高估mGFRiohexol,eGFRcys低估mGFRiohexol。作者认为这种高估和低估可能分别与危重患者肾小管肌酐分泌增加和胱抑素C生成增加有关。
要点
- 危重患者增强CT后高剂量碘海醇测得的mGFRiohexol与低剂量碘海醇结果强正相关(R2 = 0.88;p < 0.001),支持利用CT时给予的高剂量碘海醇测定GFR。
- mGFRiohexol与6小时uClcr强正相关(R2 = 0.87;p < 0.001),但uClcr均值(97.3 ± 58.2 mL/min,n = 25)高于mGFRiohexol均值(77.4 ± 38.1 mL/min,n = 26)。
- 在危重患者中eGFRcr高估mGFRiohexol、eGFRcys低估mGFRiohexol,作者认为可能与肾小管肌酐分泌增加和胱抑素C生成增加有关。
- 高剂量与低剂量碘海醇mGFRiohexol的一致性分析是在mGFRiohexol正常或偏高的患者中进行的(R2 = 0.88;p < 0.001)。
适用人群与场景
- 瑞典东南部多个ICU收治的危重成人患者。
- 纳入患者因增强CT接受了高剂量碘海醇(范围27-140 mL)。
处置流程与药物剂量
- 增强CT时给予高剂量碘海醇(范围27-140 mL),于消除相采血,用高效液相色谱法测定血浆碘海醇浓度并计算mGFRiohexol。
- 随后数日给予标准剂量(5 mL)碘海醇,比较低剂量与高剂量清除率结果。
- 每日4次测定6小时尿肌酐清除率(uClcr)并取平均值。
研究设计与关键结果
- 前瞻性观察性队列研究,纳入26例危重成人患者,增强CT后mGFRiohexol为77.4 ± 38.1 mL/min(n = 26),uClcr为97.3 ± 58.2 mL/min(n = 25)。
- 在mGFRiohexol正常或偏高的患者中,高剂量与低剂量碘海醇测定的mGFRiohexol强正相关(R2 = 0.88;p < 0.001)。
- mGFRiohexol与uClcr强正相关(R2 = 0.87;p < 0.001)。
- eGFRcr高估mGFRiohexol,eGFRcys低估mGFRiohexol。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 作者认为eGFRcr高估和eGFRcys低估mGFRiohexol可能分别由危重患者肾小管肌酐分泌增加和胱抑素C生成增加解释。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为增强CT后利用所给高剂量碘海醇测定mGFRiohexol与标准低剂量碘海醇测定的mGFRiohexol及uClcr比较良好,支持该新方法。
- 在危重患者中解读eGFRcr和eGFRcys时需注意前者高估、后者低估mGFRiohexol,作者认为这与肾小管肌酐分泌增加和胱抑素C生成增加有关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To measure glomerular filtration rate using iohexol plasma clearance (mGFRiohexol) in critically ill patients using the high doses of iohexol administered at CT and to evaluate its agreements with urinary creatinine clearance (uClcr) and estimated glomerular filtration rates (eGFRs), calculated from plasma concentrations of creatinine (eGFRcr) and cystatin C (eGFRcys).
DESIGN: Prospective observational cohort study.
SETTING: ICUs across Southeast Sweden.
PATIENTS: Critically ill adult patients.
INTERVENTIONS AND MEASUREMENTS: Twenty-six ICU patients were given high doses of iohexol (range, 27-140 mL) for contrast-enhanced CT, whereafter blood samples were taken in the elimination phase for determination of mGFRiohexol. Plasma iohexol concentrations were determined by high-performance liquid chromatography and mGFRiohexol was calculated. Standard dose (5 mL) of iohexol was administered the following days to compare low-dose clearance results with the high-dose clearance results. Six-hour uClcr was performed four times a day and averaged.
MAIN RESULTS: Mean ± sd mGFRiohexol after CT was 77.4 ± 38.1 mL/min (n = 26), and uClcr was 97.3 ± 58.2 mL/min (n = 25) in the critically ill patients. There was a strong positive correlation between mGFRiohexol determined with high and low doses of iohexol in patients with normal or high mGFRiohexol (coefficient of determination [R2] = 0.88; p < 0.001) and between mGFRiohexol and uClcr (R2 = 0.87; p < 0.001). eGFRcr overestimated mGFRiohexol and eGFRcys underestimated mGFRiohexol.
CONCLUSIONS: mGFRiohexol after contrast-enhanced CT compares well with mGFRiohexol after standard low-dose iohexol respectively uClcr. Over- and underestimation of mGFRiohexol by eGFRcr and eGFRcys is probably explained by increased tubular secretion of creatinine and increased production of cystatin C in intensive care patients.
参考来源
- Kågedal B, Helldén A, Nezirević Dernroth D, et al. Determination of Glomerular Filtration Rate After Contrast-Enhanced CT Among Critically Ill Patients: Support for a New Procedure. Crit Care Explor. 2025. PMID: 40366295. doi:10.1097/CCE.0000000000001269
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。